The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Nipranol     [8-[2-hydroxy-3-(propan-2...

Synonyms: Hypadil, Nipradilol, Nipradolol, Nipradilolum, Hypadil (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Nipradilol


High impact information on Nipradilol

  • RESULTS: Twice-daily 7-day instillation of nipradilol temporarily but significantly increased human ONH blood velocity, in the ipsilateral eye only (P = 0.005), independent of a reduction in the intraocular pressure [5].
  • Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys [5].
  • Second, nipradilol or timolol was instilled, and their effects on intravitreal injection of endothelin-1-induced retinal artery contraction were compared, to evaluate whether a pharmacologically active level of nipradilol penetrates the inner limiting layer by topical application [6].
  • Coadministration of nipradilol with NMDA reduced cell numbers in the GCL and IPL thickness to 67.8% +/- 2.2% and 74.4% +/- 5.2% of control, respectively (P: < 0.05-0.01) [6].
  • PURPOSE: To study the effects of nipradilol, a nonselective beta-blocker with alpha 1-blocking activity and nitroglycerin-like activity, on aqueous humor dynamics and optic nerve head (ONH) circulation in albino rabbits [7].

Chemical compound and disease context of Nipradilol


Biological context of Nipradilol


Anatomical context of Nipradilol


Associations of Nipradilol with other chemical compounds

  • The percentage of portal pressure reduction and the frequency of nonresponders did not differ between the nipradilol and propranolol groups [8].
  • Effects of nicorandil and nipradilol on ischemic myocardium in perfused rat heart [4].
  • Treatment of cortical cultures with a high concentration (500 microM) of nipradilol significantly reduced cell viability, increased lactate dehydrogenase (LDH) release and nitrite concentration in culture medium, whereas desnitro-nipradilol (3,4-dihydro-8-(2-hydroxy-3-isopropylamino)propoxy-3-hydroxy-2H-1-benzopyran) had no significant effects [15].
  • Varying concentrations of two NO donors, sodium nitroprusside (SNP) and nipradilol, were added to medium with or without an NO scavenger, a soluble guanylyl cyclase inhibitor, or a PKG inhibitor [16].
  • Compared with control, infarct size was reduced by ischemic preconditioning (26%+/-4% versus 49%+/-3%, IPC versus control; p<0.01), L-arginine (24%+/-2%; p<0.01 versus control), and nipradilol (24%+/-2%; p<0.01 versus control) [17].

Gene context of Nipradilol


Analytical, diagnostic and therapeutic context of Nipradilol


  1. Hemodynamic effects of nipradilol, a new beta-adrenergic antagonist combined with a nitroxy base, in rats with intra- or extra-hepatic portal hypertension. Ohsuga, M., Cailmail, S., Lebrec, D. J. Hepatol. (1993) [Pubmed]
  2. Effects of nipradilol on myocardial ischaemia produced by coronary stenosis in dogs. Noguchi, K., Sakanashi, M. Br. J. Pharmacol. (1987) [Pubmed]
  3. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis. Sugano, S., Kawafune, T., Suzuki, T., Kubota, M., Okajima, T., Sumino, Y., Akita, H. Am. J. Gastroenterol. (1995) [Pubmed]
  4. Effects of nicorandil and nipradilol on ischemic myocardium in perfused rat heart. Haneda, T., Ichihara, K., Onodera, S. Eur. J. Pharmacol. (1989) [Pubmed]
  5. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Mizuno, K., Koide, T., Saito, N., Fujii, M., Nagahara, M., Tomidokoro, A., Tamaki, Y., Araie, M. Invest. Ophthalmol. Vis. Sci. (2002) [Pubmed]
  6. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Mizuno, K., Koide, T., Yoshimura, M., Araie, M. Invest. Ophthalmol. Vis. Sci. (2001) [Pubmed]
  7. Effects of topical nipradilol, a beta-blocking agent with alpha-blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation. Kanno, M., Araie, M., Tomita, K., Sawanobori, K. Invest. Ophthalmol. Vis. Sci. (1998) [Pubmed]
  8. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol. Aramaki, T., Sekiyama, T., Katsuta, Y., Kurokawa, H., Komeichi, H., Tsutsui, H., Terada, H., Ohsuga, M., Satomura, K., Okumura, H. J. Hepatol. (1992) [Pubmed]
  9. Long-term treatment with nipradilol, a nitric oxide-releasing beta-adrenergic blocker, enhances postischemic recovery and limits infarct size. Suematsu, Y., Ohtsuka, T., Horimoto, H., Maeda, K., Nakai, Y., Mieno, S., Takamoto, S. Ann. Thorac. Surg. (2002) [Pubmed]
  10. Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Kanno, M., Araie, M., Koibuchi, H., Masuda, K. The British journal of ophthalmology. (2000) [Pubmed]
  11. Effect of the vasodilatory beta-blocker, nipradilol, and Ca-antagonist, barnidipine, on insulin sensitivity in patients with essential hypertension. Kosegawa, I., Inaba, M., Morita, T., Awata, T., Katayama, S. Clin. Exp. Hypertens. (1998) [Pubmed]
  12. Beneficial effect of nipradilol (K-351) on acute myocardial ischemia. Study of the relationship between regional myocardial blood flow and energy metabolism. Okamoto, Y., Matsubara, T., Iyeda, N., Miyajima, K., Iida, K., Nishida, T., Kobayashi, S., Kakinuma, Y., Itoh, K., Hibi, N. Jpn. J. Pharmacol. (1990) [Pubmed]
  13. Axonal regeneration of cat retinal ganglion cells is promoted by nipradilol, an anti-glaucoma drug. Watanabe, M., Tokita, Y., Yata, T. Neuroscience (2006) [Pubmed]
  14. Some effects of nipradilol, a beta-antagonist possessing a nitroxy group, on smooth muscle of the pig coronary artery. Abe, S., Nakamura, M., Kanaide, H. Br. J. Pharmacol. (1996) [Pubmed]
  15. Nitric oxide-mediated effect of nipradilol, an alpha- and beta-adrenergic blocker, on glutamate neurotoxicity in rat cortical cultures. Taguchi, R., Shirakawa, H., Yamaguchi, T., Kume, T., Katsuki, H., Akaike, A. Eur. J. Pharmacol. (2006) [Pubmed]
  16. cAMP-responsive element binding protein mediates a cGMP/protein kinase G-dependent anti-apoptotic signal induced by nitric oxide in retinal neuro-glial progenitor cells. Nagai-Kusuhara, A., Nakamura, M., Mukuno, H., Kanamori, A., Negi, A., Seigel, G.M. Exp. Eye Res. (2007) [Pubmed]
  17. Nitric oxide-generating beta-adrenergic blocker nipradilol preserves postischemic cardiac function. Horimoto, H., Saltman, A.E., Gaudette, G.R., Krukenkamp, I.B. Ann. Thorac. Surg. (1999) [Pubmed]
  18. Up-regulation of endothelial nitric oxide synthase through beta(2)-adrenergic receptor--the role of a beta-blocker with NO-releasing action. Jayachandran, M., Hayashi, T., Sumi, D., Thakur, N.K., Kano, H., Ignarro, L.J., Iguchi, A. Biochem. Biophys. Res. Commun. (2001) [Pubmed]
  19. Cytoprotection by nipradilol, an anti-glaucomatous agent, via down-regulation of apoptosis related gene expression and activation of NF-kappaB. Ando, A., Yamazaki, Y., Kaneko, S., Miyake, M., Nambu, R., Taomoto, M., Unezaki, S., Okuda-Ashitaka, E., Okumura, T., Ito, S., Matsumura, M. Exp. Eye Res. (2005) [Pubmed]
  20. Effects of nipradilol, a nitric oxide-releasing beta-adrenoceptor blocking agent, on phosphoenolpyruvate carboxykinase gene transcription in a rat hepatoma cell line. Yamauchi, K., Nakajima, K., Ikeo, S., Nishimura, Y., Komatsu, M., Aizawa, T., Hashizume, K. Jpn. J. Pharmacol. (2001) [Pubmed]
  21. The effect of nipradilol, an alpha-beta blocker, on retinal blood flow in healthy volunteers. Kida, T., Sugiyama, T., Harino, S., Kitanishi, K., Ikeda, T. Curr. Eye Res. (2001) [Pubmed]
  22. Effect of nipradilol on cardiovascular hemodynamics during exercise in angina pectoris with old myocardial infarction. Saito, T., Sekiya, T., Yamazaki, Y., Makita, K., Udaka, Y., Inagaki, Y. Arzneimittel-Forschung. (1992) [Pubmed]
WikiGenes - Universities